Kintara Therapeutics, Inc. (KTRA)
| Market Cap | 18.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.42M |
| Shares Out | 65.53M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,696,984 |
| Open | 0.310 |
| Previous Close | 0.301 |
| Day's Range | 0.285 - 0.340 |
| 52-Week Range | 0.141 - 2.850 |
| Beta | 1.72 |
| Analysts | Buy |
| Price Target | 3.23 (+1,033.3%) |
| Earnings Date | May 13, 2022 |
About KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic b... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for KTRA stock is "Buy." The 12-month stock price forecast is 3.23, which is an increase of 1,033.33% from the latest price.
News
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference
SAN DIEGO , June 21, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapi...
Why Kintara Therapeutics Shares Are Skyrocketing Today
Kintara Therapeutics Inc (NASDAQ: KTRA) shares are trading higher by 28.6% to $0.24 after the FDA granted Fast Track Designation to the company's VAL-083. Fast Track is a process designed to facilitate ...
3 Red Hot Penny Stocks Under $1 To Watch Before Next Week
There are over 500 Nasdaq & NYSE listed stocks, right, and warrants… The post 3 Red Hot Penny Stocks Under $1 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information...
Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma
SAN DIEGO , June 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapi...
Best Tips for Buying Penny Stocks in 2022? 3 to Know
Here's what you need to know about buying penny stocks in 2022 The post Best Tips for Buying Penny Stocks in 2022? 3 to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...
Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference
SAN DIEGO , June 10, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapi...
Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
SAN DIEGO , June 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapie...
Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma
SAN DIEGO , May 27, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapie...
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO , May 13, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapie...
Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading
Here's what you need to know about trading penny stocks on April 27th The post Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading appeared first on Penny Stocks to Buy, Picks, News and Infor...
Best Penny Stocks to Buy Under $2? 3 to Watch in May
Are these under $2 penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Under $2?
Kintara Therapeutics to Present at the Planet MicroCap Showcase 2022
SAN DIEGO , April 26, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO , April 14, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO , April 12, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Popular Penny Stocks to Buy in April? 3 to Watch Right Now
Check these three penny stocks out in April 2022 The post Popular Penny Stocks to Buy in April? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual Meeting
SAN DIEGO , April 11, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
SAN DIEGO , March 22, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting
SAN DIEGO , March 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapie...
Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022
SAN DIEGO, Feb. 4, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Pr...
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Tar...
SAN DIEGO, Feb. 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies...
Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's ...
SAN DIEGO, Jan. 12, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapie...
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference
SAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Ch...
Kintara Therapeutics to Present at the MedInvest Oncology Investor Conference on December 9, 2021
SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Ch...